Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma

Glioblastoma (GBM) is an ideal candidate disease for signal transduction targeted therapy because the majority of these tumors harbor genetic alterations that result in aberrant activation of growth factor signaling pathways. Loss of heterozygosity of chromosome 10, mutations in the tumor suppressor...

Descripción completa

Detalles Bibliográficos
Autores principales: Koul, Dimpy, Wang, Shuzhen, Wu, Shaofang, Saito, Norihiko, Zheng, Siyuan, Gao, Feng, Kaul, Isha, Setoguchi, Masaki, Nakayama, Kiyoshi, Koyama, Kumiko, Shiose, Yoshinobu, Sulman, Erik P., Hirota, Yasuhide, Yung, W.K. Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400620/
https://www.ncbi.nlm.nih.gov/pubmed/28423515
http://dx.doi.org/10.18632/oncotarget.15566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400620/
https://www.ncbi.nlm.nih.gov/pubmed/28423515
http://dx.doi.org/10.18632/oncotarget.15566

Ejemplares similares